Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,037 public trials 564 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Active, Not Recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748

Conditions
AML/MDS, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, +33 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • TriStar Bone Marrow Transplant Nashville, Tennessee, United States
View Trial Details
Active, Not Recruiting

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

NCT04155749

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Advanced Cellular Therapeutics Facility, DCAM 0800A Chicago, Illinois, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Froedtert Hospital/Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Active, Not Recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024

Conditions
Blood Protein Disorders, COVID-19, COVID-19 Infection, +30 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Johns Hopkins University Baltimore, Maryland, United States
  • U Mass Chan Medical School Worcester, Massachusetts, United States
  • SUNY-Stony Brook Stony Brook, New York, United States
View Trial Details
Active, Not Recruiting

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

NCT05396885

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • HonorHealth Cancer Transplant Institute Scottsdale, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

NCT04221178

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
View Trial Details
Active, Not Recruiting

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Alfred Hospital Melbourne, Australia
  • University Hospital Leuven Leuven, Belgium
  • University Hospital Ostrava Ostrava, Czechia
  • Odense University Hospital Odense, Denmark
View all 13 locations
View Trial Details

Related conditions